Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 upadacitinib + topical corticosteroids in moderate to severe atopic dermatitis
jRCT2080224016Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Upadacitinib + topical corticosteroids with Placebo + topical corticosteroids (2 arms). Started Aug 2018; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224016.